Suchen
Agenus Inc
AGENZur Watchlist hinzufügen
3.580USD
0.0000.00%
Handelsschluss 05/15, 16:00（ET）Kurse um 15 Minuten verzögert
149.08MMarktkapitalisierung
1.73KGV TTM
mehr Informationen über Agenus Inc Unternehmen
Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Agenus Inc Informationen
BörsenkürzelAGEN
Name des UnternehmensAgenus Inc
IPO-datumFeb 04, 2000
CEOArmen (Garo H)
Anzahl der mitarbeiter316
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 04
Addresse3 Forbes Rd
StadtLEXINGTON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl02421-7305
Telefon17816744400
Websitehttps://agenusbio.com/
BörsenkürzelAGEN
IPO-datumFeb 04, 2000
CEOArmen (Garo H)
Führungskräfte von Agenus Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Thomas L. (Tom) Harrison, Ph.D.
Mr. Thomas L. (Tom) Harrison, Ph.D.
Independent Director
Independent Director
39.00K
+23.66%
Ms. Christine M. Klaskin
Ms. Christine M. Klaskin
Vice President - Finance
Vice President - Finance
23.48K
+67.22%
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
4.60K
--
Wright (Timothy R)
Wright (Timothy R)
Lead Independent Director
Lead Independent Director
2.77K
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Jennifer S. Buell, Ph.D.
Dr. Jennifer S. Buell, Ph.D.
Director
Director
--
--
Ms. Susan F. Hirsch
Ms. Susan F. Hirsch
Independent Director
Independent Director
--
--
Dr. Steven O'Day, M.D.
Dr. Steven O'Day, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Richard Goldberg
Mr. Richard Goldberg
Chief Development Officer
Chief Development Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Thomas L. (Tom) Harrison, Ph.D.
Mr. Thomas L. (Tom) Harrison, Ph.D.
Independent Director
Independent Director
39.00K
+23.66%
Ms. Christine M. Klaskin
Ms. Christine M. Klaskin
Vice President - Finance
Vice President - Finance
23.48K
+67.22%
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
4.60K
--
Wright (Timothy R)
Wright (Timothy R)
Lead Independent Director
Lead Independent Director
2.77K
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Jennifer S. Buell, Ph.D.
Dr. Jennifer S. Buell, Ph.D.
Director
Director
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Apr 6
Währung: USDAktualisiert: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Non-cash royalty revenue
108.59M
95.09%
Pre-commercial product revenue
4.24M
3.71%
Other services
1.04M
0.91%
Clinical product revenue
334.00K
0.29%
Nach RegionUSD
Name
Umsatz
Anteil
United States
113.16M
99.09%
Rest of World
1.04M
0.91%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Non-cash royalty revenue
108.59M
95.09%
Pre-commercial product revenue
4.24M
3.71%
Other services
1.04M
0.91%
Clinical product revenue
334.00K
0.29%
Aktionärsstatistik
Aktualisiert: Wed, May 13
Aktualisiert: Wed, May 13
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Zydus Lifesciences Ltd
5.12%
Vanguard Capital Management, LLC
3.46%
Vanguard Portfolio Management, LLC
2.87%
Invus Public Equities Advisors, LLC
2.56%
Renaissance Technologies LLC
1.31%
Andere
84.69%
Aktionäre
Aktionäre
Anteil
Zydus Lifesciences Ltd
5.12%
Vanguard Capital Management, LLC
3.46%
Vanguard Portfolio Management, LLC
2.87%
Invus Public Equities Advisors, LLC
2.56%
Renaissance Technologies LLC
1.31%
Andere
84.69%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
13.72%
Investment Advisor/Hedge Fund
5.42%
Hedge Fund
5.15%
Corporation
5.14%
Individual Investor
1.56%
Research Firm
1.12%
Pension Fund
0.91%
Andere
66.99%
Institutionelle Beteiligung
Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
275
10.91M
26.27%
-968.40K
2025Q4
304
9.95M
37.38%
--
2025Q3
332
9.95M
41.39%
+217.92K
2025Q2
334
9.73M
47.54%
+407.61K
2025Q1
334
9.33M
45.75%
-2.82M
2024Q4
341
8.45M
52.98%
-249.79K
2024Q3
351
8.70M
54.68%
-447.45K
2024Q2
347
9.21M
64.12%
-1.91M
2024Q1
356
10.69M
65.28%
-2.98M
2023Q4
374
11.90M
61.88%
+645.94K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Zydus Lifesciences Ltd
2.13M
5.56%
+2.13M
--
Jan 15, 2026
Invus Public Equities Advisors, LLC
1.06M
2.77%
--
--
Dec 31, 2025
Renaissance Technologies LLC
543.55K
1.42%
+477.35K
+721.07%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
485.30K
1.26%
+16.52K
+3.52%
Dec 31, 2025
Citadel Advisors LLC
423.24K
1.1%
+423.24K
--
Dec 31, 2025
Armen (Garo H.)
394.77K
1.03%
+8.98K
+2.33%
Mar 20, 2026
Geode Capital Management, L.L.C.
372.75K
0.97%
+25.76K
+7.42%
Dec 31, 2025
Wellington Management Company, LLP
290.65K
0.76%
--
--
Dec 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0%
iShares Russell 3000 ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Fidelity Enhanced Small Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Schwab U.S. Small-Cap ETF
0%
SPDR Portfolio MSCI Global Stock Market ETF
0%
Global X Russell 2000 ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
Mehr Anzeigen
iShares Micro-Cap ETF
Anteil0.02%
iShares Russell 2000 Growth ETF
Anteil0%
iShares Russell 3000 ETF
Anteil0%
Invesco NASDAQ Future Gen 200 ETF
Anteil0%
Fidelity Enhanced Small Cap ETF
Anteil0%
iShares Core S&P Total U.S. Stock Market ETF
Anteil0%
Schwab U.S. Small-Cap ETF
Anteil0%
SPDR Portfolio MSCI Global Stock Market ETF
Anteil0%
Global X Russell 2000 ETF
Anteil0%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Datum
Ex-Dividendentag
Art
Verhältnis
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
